Clinical Trial Update: 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

View source ↗

Summary

A clinical trial evaluating 18F-FES PET/CT guided first-line treatment for HR+/HER2- metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Status: COMPLETED